Mahmood Ahmad
Tahir Heart Institute
author@example.com

CT.gov Industry Family Repeaters

Which industry sponsors keep reappearing once older CT.gov studies are split by intervention family rather than treated as one pooled industry backlog? We analysed 249,507 eligible older closed interventional studies from the March 29, 2026 full-registry snapshot and isolated industry-sponsored records with intervention families and country locations. The project compares sponsor-level missing-results counts, no-results rates, ghost-protocol rates, and geography contrasts across drug, device, procedure, biological, and dietary-supplement industry portfolios. In drug studies, GlaxoSmithKline carried 1,033 missing-results studies, ahead of Boehringer Ingelheim at 847 and AstraZeneca at 845. Industry procedure studies were smaller but still uneven, while industry no-results rates rose from 27.3 percent in mixed U.S.-plus-non-U.S. portfolios to 70.9 percent in no-U.S. portfolios and 65.9 percent in selected no-country records. Industry hiddenness therefore depends strongly on modality and geography, so a pooled industry leaderboard understates where backlog concentrates most severely. Industry, sponsor, and intervention labels are registry-entered fields rather than audited corporate, legal, or therapeutic classifications.

Outside Notes

Type: methods
Primary estimand: Industry sponsor missing-results counts within intervention families among eligible older CT.gov studies
App: CT.gov Industry Family Repeaters dashboard
Data: 249,507 eligible older closed interventional studies, with industry records grouped by intervention family and geography
Code: https://github.com/mahmood726-cyber/ctgov-industry-family-repeaters
Version: 1.0.0
Validation: FULL REGISTRY RUN

References

1. ClinicalTrials.gov API v2. National Library of Medicine. Accessed March 29, 2026.
2. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov. N Engl J Med. 2016;375(20):1998-2004.
3. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361-369.

AI Disclosure

This work represents a compiler-generated evidence micro-publication built from structured registry data and deterministic summary code. AI was used as a constrained coding and drafting assistant for interface generation, packaging, and prose refinement, not as an autonomous author. The analytical choices, interpretation, and final outputs were reviewed by the author, who takes responsibility for the content.